 Sarah Johnson
Concepts (174)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 12 | 2023 | 3050 | 0.850 |
Why?
| | Pancreatic Neoplasms | 3 | 2009 | 210 | 0.700 |
Why?
| | Insulin-Like Growth Factor Binding Protein 5 | 2 | 2009 | 16 | 0.580 |
Why?
| | Gene Expression Profiling | 10 | 2023 | 1108 | 0.580 |
Why?
| | Adenocarcinoma | 3 | 2007 | 404 | 0.570 |
Why?
| | Gene Expression | 4 | 2018 | 623 | 0.560 |
Why?
| | Cysteine-Rich Protein 61 | 1 | 2014 | 3 | 0.450 |
Why?
| | Candidiasis, Invasive | 2 | 2024 | 11 | 0.440 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2021 | 856 | 0.420 |
Why?
| | Bone Diseases | 1 | 2014 | 95 | 0.410 |
Why?
| | Tumor Microenvironment | 1 | 2014 | 254 | 0.390 |
Why?
| | Plasma Cells | 4 | 2021 | 239 | 0.360 |
Why?
| | Snacks | 2 | 2021 | 3 | 0.350 |
Why?
| | Evolution, Molecular | 2 | 2021 | 95 | 0.340 |
Why?
| | Spinal Cord Stimulation | 2 | 2022 | 43 | 0.340 |
Why?
| | Vegetables | 2 | 2021 | 66 | 0.330 |
Why?
| | Neoplasm Proteins | 2 | 2021 | 328 | 0.280 |
Why?
| | Kallikreins | 1 | 2007 | 19 | 0.270 |
Why?
| | Cadherins | 1 | 2007 | 63 | 0.260 |
Why?
| | Mutation | 4 | 2021 | 1342 | 0.260 |
Why?
| | Bone Marrow | 3 | 2018 | 363 | 0.260 |
Why?
| | Neoplasm Invasiveness | 1 | 2007 | 278 | 0.250 |
Why?
| | Prognosis | 6 | 2021 | 2115 | 0.240 |
Why?
| | Cell Cycle | 2 | 2021 | 240 | 0.240 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 412 | 0.240 |
Why?
| | Muscle Spasticity | 2 | 2022 | 13 | 0.230 |
Why?
| | Receptors, GABA-A | 1 | 2005 | 11 | 0.230 |
Why?
| | Antifungal Agents | 2 | 2024 | 346 | 0.230 |
Why?
| | Protein Subunits | 1 | 2005 | 79 | 0.230 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2005 | 38 | 0.230 |
Why?
| | Humans | 27 | 2024 | 52513 | 0.220 |
Why?
| | Candidemia | 1 | 2023 | 8 | 0.210 |
Why?
| | Cell Line, Tumor | 4 | 2014 | 1435 | 0.200 |
Why?
| | Chronic Pain | 2 | 2022 | 178 | 0.200 |
Why?
| | Rhizotomy | 1 | 2022 | 3 | 0.190 |
Why?
| | Neuralgia | 1 | 2022 | 42 | 0.190 |
Why?
| | Disease Progression | 4 | 2021 | 872 | 0.180 |
Why?
| | Muscle Relaxants, Central | 1 | 2021 | 5 | 0.180 |
Why?
| | Baclofen | 1 | 2021 | 11 | 0.180 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2021 | 48 | 0.180 |
Why?
| | Ubiquitination | 1 | 2021 | 57 | 0.180 |
Why?
| | Lymphoma, B-Cell | 1 | 2021 | 62 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 642 | 0.170 |
Why?
| | Cell Cycle Proteins | 1 | 2021 | 168 | 0.170 |
Why?
| | B-Lymphocytes | 1 | 2021 | 180 | 0.170 |
Why?
| | Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.160 |
Why?
| | Complex Regional Pain Syndromes | 1 | 2020 | 14 | 0.160 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 80 | 0.160 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 77 | 0.150 |
Why?
| | Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 10 | 0.150 |
Why?
| | Pain Management | 1 | 2020 | 177 | 0.150 |
Why?
| | Hematopoietic Stem Cells | 1 | 2019 | 188 | 0.140 |
Why?
| | Adipocytes | 1 | 2018 | 130 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2019 | 202 | 0.140 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 2 | 2018 | 125 | 0.130 |
Why?
| | Health Promotion | 1 | 2020 | 268 | 0.130 |
Why?
| | Biopsy | 2 | 2018 | 603 | 0.130 |
Why?
| | Child | 6 | 2024 | 7218 | 0.120 |
Why?
| | Male | 12 | 2024 | 26816 | 0.120 |
Why?
| | Cell Proliferation | 3 | 2023 | 1027 | 0.120 |
Why?
| | Female | 12 | 2024 | 28219 | 0.110 |
Why?
| | Neoplasm, Residual | 1 | 2016 | 173 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 582 | 0.110 |
Why?
| | Asymptomatic Diseases | 1 | 2014 | 38 | 0.110 |
Why?
| | Immunohistochemistry | 2 | 2007 | 981 | 0.110 |
Why?
| | Treatment Outcome | 5 | 2024 | 5480 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2016 | 327 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2015 | 292 | 0.100 |
Why?
| | Palliative Care | 1 | 2015 | 215 | 0.100 |
Why?
| | Aged | 6 | 2021 | 10181 | 0.090 |
Why?
| | Molecular Targeted Therapy | 1 | 2011 | 133 | 0.080 |
Why?
| | Bone and Bones | 1 | 2014 | 494 | 0.080 |
Why?
| | Hospitalization | 1 | 2015 | 749 | 0.080 |
Why?
| | Risk Factors | 4 | 2023 | 3951 | 0.080 |
Why?
| | Animals | 3 | 2021 | 13464 | 0.080 |
Why?
| | Cohort Studies | 2 | 2024 | 1551 | 0.080 |
Why?
| | Culture Media, Conditioned | 1 | 2009 | 48 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2014 | 1481 | 0.080 |
Why?
| | Enzyme Activation | 1 | 2009 | 269 | 0.080 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2009 | 155 | 0.080 |
Why?
| | Signal Transduction | 2 | 2021 | 1707 | 0.080 |
Why?
| | Mice | 2 | 2021 | 5943 | 0.080 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2009 | 149 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2023 | 3414 | 0.070 |
Why?
| | Genes, Neoplasm | 1 | 2008 | 31 | 0.070 |
Why?
| | Parents | 2 | 2021 | 332 | 0.070 |
Why?
| | Middle Aged | 5 | 2021 | 13081 | 0.070 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 371 | 0.070 |
Why?
| | Adolescent | 3 | 2024 | 6725 | 0.070 |
Why?
| | Risk Assessment | 1 | 2011 | 1348 | 0.070 |
Why?
| | Microfilament Proteins | 1 | 2006 | 44 | 0.060 |
Why?
| | Calcium-Binding Proteins | 1 | 2006 | 58 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2008 | 224 | 0.060 |
Why?
| | Tumor Cells, Cultured | 1 | 2006 | 448 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2006 | 460 | 0.060 |
Why?
| | Pancreatic Ducts | 1 | 2005 | 13 | 0.060 |
Why?
| | Neoplasms | 1 | 2015 | 1301 | 0.060 |
Why?
| | DNA, Complementary | 1 | 2005 | 130 | 0.060 |
Why?
| | Administration, Intravenous | 1 | 2024 | 73 | 0.060 |
Why?
| | DNA, Neoplasm | 1 | 2005 | 146 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2005 | 1139 | 0.060 |
Why?
| | Triazoles | 1 | 2024 | 114 | 0.050 |
Why?
| | ADP-Ribosylation Factors | 1 | 2003 | 15 | 0.050 |
Why?
| | Adult | 4 | 2022 | 14148 | 0.050 |
Why?
| | Prospective Studies | 2 | 2022 | 2451 | 0.050 |
Why?
| | Paresis | 1 | 2022 | 7 | 0.050 |
Why?
| | Spinal Cord | 1 | 2022 | 131 | 0.050 |
Why?
| | Hemiplegia | 1 | 2022 | 11 | 0.050 |
Why?
| | Syndrome | 1 | 2022 | 252 | 0.050 |
Why?
| | Infusion Pumps, Implantable | 1 | 2021 | 14 | 0.050 |
Why?
| | Injections, Spinal | 1 | 2021 | 21 | 0.050 |
Why?
| | Syndecan-1 | 1 | 2021 | 73 | 0.040 |
Why?
| | Food Preferences | 1 | 2021 | 15 | 0.040 |
Why?
| | Taste | 1 | 2021 | 31 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2021 | 128 | 0.040 |
Why?
| | Mutation Rate | 1 | 2021 | 36 | 0.040 |
Why?
| | Remission Induction | 1 | 2021 | 219 | 0.040 |
Why?
| | Clone Cells | 1 | 2021 | 76 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2022 | 182 | 0.040 |
Why?
| | Logistic Models | 1 | 2023 | 934 | 0.040 |
Why?
| | Genes, Tumor Suppressor | 1 | 2021 | 73 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 69 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 117 | 0.040 |
Why?
| | Genome, Human | 1 | 2021 | 121 | 0.040 |
Why?
| | Audiovisual Aids | 1 | 2020 | 13 | 0.040 |
Why?
| | Alleles | 1 | 2021 | 277 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2021 | 563 | 0.040 |
Why?
| | Transcription Factors | 1 | 2023 | 566 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2022 | 6661 | 0.040 |
Why?
| | Video Recording | 1 | 2020 | 79 | 0.040 |
Why?
| | Young Adult | 2 | 2022 | 4326 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 681 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2020 | 180 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2021 | 602 | 0.040 |
Why?
| | Translocation, Genetic | 1 | 2021 | 265 | 0.040 |
Why?
| | Students | 1 | 2020 | 228 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 952 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 673 | 0.030 |
Why?
| | Infant | 1 | 2024 | 3713 | 0.030 |
Why?
| | Child, Preschool | 1 | 2024 | 4056 | 0.030 |
Why?
| | Integrins | 1 | 2016 | 31 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2018 | 673 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2016 | 117 | 0.030 |
Why?
| | Prednisone | 1 | 2016 | 102 | 0.030 |
Why?
| | Cell Adhesion Molecules | 1 | 2016 | 88 | 0.030 |
Why?
| | Models, Genetic | 1 | 2016 | 172 | 0.030 |
Why?
| | Hospices | 1 | 2015 | 11 | 0.030 |
Why?
| | Transcriptome | 1 | 2018 | 367 | 0.030 |
Why?
| | Melphalan | 1 | 2016 | 181 | 0.030 |
Why?
| | Down-Regulation | 1 | 2016 | 344 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2020 | 2290 | 0.030 |
Why?
| | Time Factors | 1 | 2021 | 2997 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2015 | 150 | 0.030 |
Why?
| | Genomics | 1 | 2016 | 270 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1030 | 0.030 |
Why?
| | Thalidomide | 1 | 2016 | 378 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2015 | 284 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2015 | 403 | 0.030 |
Why?
| | Dexamethasone | 1 | 2016 | 439 | 0.030 |
Why?
| | Phenotype | 1 | 2016 | 800 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 361 | 0.020 |
Why?
| | Physicians | 1 | 2015 | 241 | 0.020 |
Why?
| | Gene Deletion | 1 | 2008 | 275 | 0.020 |
Why?
| | DNA Damage | 1 | 2008 | 307 | 0.020 |
Why?
| | Substantia Nigra | 1 | 2003 | 14 | 0.010 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2003 | 75 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2003 | 181 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2003 | 150 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 634 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 572 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 770 | 0.010 |
Why?
| | Myocardium | 1 | 2003 | 479 | 0.010 |
Why?
| | DNA | 1 | 2003 | 548 | 0.010 |
Why?
| | Kidney | 1 | 2003 | 723 | 0.010 |
Why?
|
|
Johnson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|